*** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!

This interactive course provides an advanced, practical detailed interactive review of the organizational fundamentals of Good Clinical Practice (GCP). Participants will acquire real-world application of GCP regulations and guidelines for critical elements of the clinical research and development process. This training includes the updates brought by the ICH E6 R2 Addendum.

During this interactive workshop, we will debate in what way clinical research team members can apply systems to achieve data integrity and quality through the trial lifecycle.

Specific attention will be given to how quality systems affect overall data integrity, patient clinical risk, and respective regulatory risk.

Seminar Fee Includes:

Lunch

AM-PM Tea/Coffee

Seminar Material

Attendance Certificate

$100 Gift Cert for next seminar

Learning Objectives:

Learn how to:

• Describe the elements of functional Quality Systems for Sponsors, Institutional Review Boards (IRBs), and Clinical Investigators
• Identify the universal and local components of GCP
• Explain the differences between the legal and procedural elements of GCP
• Describe the overlap between GCP and Good Manufacturing Practice (GMP)
• Recognize key differences in pharmaceutical, device, and biologics GCP
• Examine recent trends in non-compliance
• Develop and implement site-specific approaches for corrective action of non-compliance

Areas Covered:

• Principles of GCP: Different Perspectives: Examination; application; implementation
• New Developments and Emerging Trends in GCP
• The “Forgotten” Elements of GCP: Regulations; laws; guidelines
• Quality Systems: The Roadmap to GCP: Quality control; quality assurance; quality improvement
• Quality Risk Management (QRM) in Clinical Trials: Application of risk assessment in the review of protocols
• The Role of Standard Operating Procedures in GCP: Rationale; development; training; implementation; maintenance
• GCP Across Investigational Products: Drugs; devices; biologics
• Are We There Yet? Recent non-compliance issues with discussion of Corrective and Preventive Action planning

Who will Benefit:

This program is designed for professionals with two to three years of experience in the clinical research industry. Clinical Research Associates, Project Managers, Investigators, Study Coordinators, and GCP Focused Regulatory Affairs Professionals.

AGENDA

DAY 01(8:30 AM - 4:30 PM)

08.30 AM - 09.00 AM - Registration, Meet and Greet.

09.00 AM - Session Start Time

Historical overview of Clinical Research

Observational studies

Case report

Case series

Cross section studies

Case control studies

Cohort studies

Phases of Clinical Development & Types of Clinical Trials

Planning and Initiating a Clinical Trial:

Role of the Sponsor:

Quality Assurance (QA) (see allocated time)

Contract Research Organizations (CROs)

Trial / Protocol Design

Trial Conduct & Management

Investigator Selection: Who can be an Investigator?

Sponsor Monitoring (See allocated time below)

Lunch Break

Ethics & Research Subject Protection

History of research ethics

Human Subject protection

Risk assessment

Investigator Responsibilities:

Qualifications & Agreements

Resources & Selection of the trial team: delegation, Log of study Personnel, Keeping members informed

Medical Care of trial subjects

Compliance with the protocol

Quality Assurance / Quality Control in Clinical Trials

Defining the terminology

The quality challenges

The quality plan / Operational QC

Role of Clinical Quality Assurance: What should you expect from Clinical Quality Assurance (CQA)?

GCP Audits: what you need to know

Root Cause Analysis (RCA) and Corrective and Preventive Action (CAPA) in Site Management

What is non-compliance?

Most common inspection & audit findings

Identifying the root cause

Corrective Action versus Preventative Action

What is NOT a good CAPA?

Ethics for Genetics Research

Informed Consent: The how? What? & why?

Investigational Medicinal Product & Drug Accountability

Safety Reporting:

Protocol requirements pertaining to safety

Expedited reporting of adverse events (AEs).

What makes a well-documented adverse event (AE).

What is a Suspected Unexpected Adverse Reaction (SUSAR).

Laboratory Evaluations

DAY 02(8:30 AM - 4:30 PM)

09.00 AM - Session Start Time

Drug Safety Monitoring Board (DSMB)/Independent Drug Monitoring Committee (IDMC) Clinical Trial Safety and Safety Monitoring

Background & GCP Guidelines for DSMB/IDMC

What are the processes of DSMB/IDMC Review?

Sharing Best Practice in Patient Recruitment & Subject retention

Subject Recruitment:

Recruitment prediction,

Advertising,

Avoiding pitfalls.

Lunch Break

Essential Documents To Ensure A Complete TMF Under All Regulations

Regulators’ Focus on TMF: Why?

Why should sponsors Focus on TMF?

Common Audit/Inspection TMF-related findings

Lessons learnt………. Or…. Not!

Data Quality and Archive

SPEAKER

Amer Alghabban

Managing Director, GxP Compliance and Training Partners (GCTP)

Amer Alghabban, M.Sc. (Clin. Pharmacology), Post-Grad. Cert. Clinical Research, Dipl. Bio. Sci., B.Sc., Cert. Teacher Education, M Soc. Pharm. Med., MRQA, MIQA, MDIA, ISO 9001:2015 QMS Certified Lead Auditor, IRCA Certified Lead Auditor.

Amer is currently the Managing Director of GxP Compliance and Training Partners (GCTP), which he founded, helping pharmaceutical companies & academic institutions worldwide to achieve compliance with GCP, GVP, GCLP, GDP and GLP.

Amer, a Clinical pharmacologist by education, has over 28 years’ experience in the pharmaceutical industry. He enjoys imparting his experiences, as an invited speaker at over 125 international congresses and as writer; he published 2 reference books, The Pharmaceutical Medicine Dictionary and The Dictionary of Pharmacovigilance and other publications. Amer has experience of working at the MHRA where he participated in the conduct of the very first Regulatory Authority pharmacovigilance-GCP inspection in the EU and wrote the 1st EU regulatory authority SOPs on conducting GVP inspections. He has over 21 years’ experience of directing Inspection Readiness Programs (Mock Inspections & Pre- & Post-Mock Inspection-Training) and hosting regulatory authorities’ & notified bodies’ inspections. To date, he has prepared, trained, hosted & managed over 67 Regulatory Authorities’ inspections by all major regulatory authorities (FDA, EMA, EU Authorities (CAs), Japanese PMDA, Brazilian, Chinese SFDA & Middle Eastern authorities etc.) Earlier in his career, he was Assistant Editor for 11 medical journals and was the 1st invited Course Director for The Pharmacovigilance Auditing Course at the RQA.

Amer’s other previous positions included: Vice President GxP Quality Assurance, Compliance & Training at Karyopharm Therapeutics Inc. Boston, USA, Global Director, Head of Quality Assurance at Merck Serono, Geneva, Switzerland, Global Head of GxP Quality Assurance at Arpida Ag., Switzerland, Senior International Clinical Quality Assurance Audit Manager at Novartis Headquarters, Basel, Switzerland and he was the first Pharmacovigilance Compliance Officer of the MHRA in the UK.

"Please contact the event manager Marilyn (marilyn.b.turner@nyeventslist.com ) below for:

- Multiple participant discounts

- Price quotations or visa invitation letters

- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)

- Event sponsorships

NO REFUNDS ALLOWED ON REGISTRATIONS

Service fees included in this listing.

-----------------------------------------------------------------

Metricstream Inc. - New York Events List

http://www.NyEventsList.com

http://www.BostonEventsList.com

http://www.SFBayEventsList.com

-----------------------------------------------------------------

MYL190818CEV"